ArticleLiver cancer2019
Stereotactic Body Radiation Therapy as an Alternative Treatment for Patients with Hepatocellular Carcinoma Compared to Sorafenib: A Propensity Score Analysis.
Article in Liver cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- Prospective Registry and Meta-Analysis of Particle Therapy for Hepatocellular Carcinoma: Clinical Outcomes and Real-World Impact.Cancer medicine · 2026Pooled it
- External radiotherapy combined with sorafenib has better efficacy in unresectable hepatocellular carcinoma: a systematic review and meta-analysis.Clinical and experimental medicine · 2023Pooled it
- Clinical outcomes after interstitial high-dose-rate brachytherapy vs. stereotactic body radiotherapy in hepatocellular carcinoma: A retrospective matched single-center analysis.Journal of contemporary brachytherapy · 2026Article
- Evaluating the efficacy and immunological impact of combined ICIs and SBRT in HCC: A narrative literature review.Clinical and translational radiation oncology · 2026Review
- Comparison of interstitial high-dose-rate brachytherapy and stereotactic radiotherapy in breath-hold technique for inoperable primary and secondary liver tumors.Physics and imaging in radiation oncology · 2025Article
- Stereotactic body radiation therapy (SBRT) increases anti-PD-1 antitumor activity by enhancing the tumor immune microenvironment in mice with metastatic hepatocellular carcinoma.Discover oncology · 2025Article
- A precision image-guided model of stereotactic ablative radiotherapy for hepatocellular carcinoma.Disease models & mechanisms · 2025Article
- Metastasis-directed stereotactic radiotherapy in patients with breast cancer: results of an international multicenter cohort study.Clinical & experimental metastasis · 2024Article
- Stereotactic body radiotherapy versus lenvatinib for hepatocellular carcinoma with portal vein tumor thrombosis: a propensity matching score analysis.Radiation oncology (London, England) · 2024Article
- Stereotactic body radiation therapy (SBRT) in patients with hepatocellular cancer-a narrative review and expert opinion.Journal of gastrointestinal oncology · 2024Review
- [Treatment paradigms in hepatocellular carcinoma: insights gained from the TRENDY trial].Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2023Article
- New Staging Model for Radiation-based Hepatocellular Carcinoma Treatment: A National Multicenter Study.Journal of clinical and translational hepatology · 2023Article
- Article
- Prognostic Value of a CT Radiomics-Based Nomogram for the Overall Survival of Patients with Nonmetastatic BCLC Stage C Hepatocellular Carcinoma after Stereotactic Body Radiotherapy.Journal of oncology · 2023Article
- Stereotactic body radiation therapy for hepatocellular carcinoma: From infancy to ongoing maturity.JHEP reports : innovation in hepatology · 2022Review
- Article
- Effects of Stereotactic Body Radiation Therapy Plus PD-1 Inhibitors for Patients With Transarterial Chemoembolization Refractory.Frontiers in oncology · 2022Article
- Impact of NAFLD on clinical outcomes in hepatocellular carcinoma treated with sorafenib: an international cohort study.Therapeutic advances in gastroenterology · 2022Article
- Stereotactic body radiotherapy versus intensity-modulated radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis.Hepatology international · 2021Article
- Role of modern radiotherapy in managing patients with hepatocellular carcinoma.World journal of gastroenterology · 2021Review
Corrections and comments
- Commented on by
- Erratum issuedErratum.2019
Authors and funding
27 authors at 14 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsStereotactic body radiation therapy (SBRT) has emerged as a safe and effective treatment for patients with hepatocellular carcinoma (HCC), but its role in patients with advanced HCC is not yet defined. In this study, we aim to assess the efficacy and safety of SBRT in comparison to sorafenib treatment in patients with advanced HCC.
methodsWe included 901 patients treated with sorafenib at six tertiary centers in Europe and Asia and 122 patients treated with SBRT from 13 centers in Germany and Switzerland. Medical records were reviewed including laboratory parameters, treatment characteristics and development of adverse events. Propensity score matching was performed to adjust for differences in baseline characteristics. The primary endpoint was overall survival (OS) and progression-free survival.
resultsMedian OS of SBRT patients was 18.1 (10.3-25.9) months compared to 8.8 (8.2-9.5) in sorafenib patients. After adjusting for different baseline characteristics, the survival benefit for patients treated with SBRT was still preserved with a median OS of 17.0 (10.8-23.2) months compared to 9.6 (8.6-10.7) months in sorafenib patients. SBRT treatment of intrahepatic lesions in patients with extrahepatic metastases was also associated with improved OS compared to patients treated with sorafenib in the same setting (17.0 vs. 10.0 months,
conclusionsIn this retrospective comparative study, SBRT showed superior efficacy in HCC patients compared to patients treated with sorafenib.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.